Navigation Links
LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
Date:6/5/2008

andidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended March 31, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specific
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... 11, 2014 Central Florida board-certified veterinary ... partnerships with several Brevard County animal hospitals to bring ... been working in the area since January 2006, credentialed ... 2008, and is happy to now offer his expertise ... Christiansen has used stem cell therapy with Vet-Stem, Inc. ...
(Date:9/11/2014)... The Remedy Group , a retained ... organizations, has announced that Terry Souwannamuang has joined the ... in biopharma and managed care Terry steadily rose in ... brand new specialty pharmacy for a Portland-based managed care ... Terry has a Bachelor’s Degree in General Science with ...
(Date:9/10/2014)... BASEL , Schweiz, September 11, 2014 ... Register für Eierstockkrebs, die bei der Jahresversammlung ... vorgestellt wurden, bekräftigen die komplette Tumorprofilierung als ... Bericht von Caris Registry™ zeigte ein deutlich ... mit Eierstock-, Eileiter- oder primär peritonealem Krebs, ...
(Date:9/10/2014)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a ... host a conference call and webcast tomorrow, September 11, ... time). The live call may be accessed ... participant code 38075452. The webcast can be accessed live ... site at www.orexigen.com and will be archived ...
Breaking Biology Technology:Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3The Remedy Group Announces Hiring of Managed Care and Specialty Pharmacy Veteran 2Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 2Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 3Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 4Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 5
... biomass and enzymes to produce hydrogen fuel, ethanol, and ... AgVest in Lake Delton last Thursday. , ,These ... the conference by the AgVest group, which focuses on ... specific recommendations, AgVest tries to hook up up-and-coming agricultural ...
... a PeopleSoft database for tracking alumni in favor ... used for 12 years. , ,Schools and colleges can access ... based on a database from 4D, Inc. , ... separate from the university. When the central database failed to ...
... has been less than overwhelming to Governor Jim Doyles ... private money in Wisconsins biotechnology future. Budget-conscious members of ... of stem-cell research have once again protested, and Milwaukee ... of Madison. , ,Doyle should address all legitimate gripes ...
Cached Biology Technology:Investors hear about new agricultural technology 2Alumni Association extends database help to university 2Alumni Association extends database help to university 3Wisconsin cannot afford to take a pass on Doyles biotech plan 2Wisconsin cannot afford to take a pass on Doyles biotech plan 3
(Date:9/11/2014)... treatise "Flora of Northumberland and Durham" by Nathaniel ... Books platform as an example of combining modern ... new sort of resource and data re-use. This publication ... the region, which can be seen as a model ... enriched re-publication marries the meticulous detail of old ...
(Date:9/11/2014)... Northeastern University researchers and their international colleagues have ... role of neutral evolution in the biogeographic distribution ... Thursday in the journal Science . The ... a neutral agent-based model"was co-authored by Ferdi Hellweger, ... of civil and environmental engineering; his doctoral student ...
(Date:9/11/2014)... -- Today at the TEDMED conference, Tute Genomics announced ... genome sequencing results at the fingertips of the individual ... The $1000 was announced earlier this year by Illumina, ... point towards widespread adoption of genome sequencing in research ... million variants per human genome, data analysis has become ...
Breaking Biology News(10 mins):Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 3Microbes evolve faster than ocean can disperse them 2Tute Genomics Launches MyGene Portal for Genome-guided Medicine 2Tute Genomics Launches MyGene Portal for Genome-guided Medicine 3
... Jan. 26, 2011 TGen Drug Development (TD2) ... should help speed new drugs safely into human testing ... Scottsdale, Ariz., provides drug development firms with expertise in ... regulatory approval steps of getting new drugs to patients ...
... ribbon worm discovered in Kosterhavet National Park in 2007 ... Pseudomicrura afzelii , a form of nemertean or ... at the University of Gothenburg, Sweden, using DNA technology. ... from the traditional, highly labour-intensive way of describing a ...
... 25, 2011Give caffeine to cells engineered to produce viruses used ... 8-times more virus, according to a paper published in ... Ann Liebert, Inc. ( www.liebertpub.com ). The paper is available ... inexpensive strategy for increasing lentivirus production was developed by Brian ...
Cached Biology News:Arizona companies team up, providing quick development of cancer drugs 2Researchers register new species using DNA-based description 2
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
384 well block MBSr. Robot compatible block ejection mechanism. Stackable. (384 well block - holds 384 well plate)...
...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Biology Products: